Kura Oncology, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 33.11 million compared to USD 32.74 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 0.49 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.17 USD | -1.21% | -4.51% | +47.22% |
15/05 | Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM | |
14/05 | Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.22% | 1.61B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022